Michael S. Cookson, MD, MMHC, Author at Grand Rounds in Urology

Michael S. Cookson, MD, MMHC

University of Oklahoma College of Medicine

Oklahoma City, Oklahoma

Michael S. Cookson, MD, MMHC, is Professor and Chairman of the Department of Urology and holds the Donald D. Albers Endowed Chair in Urology at the University of Oklahoma Health Sciences Center in Oklahoma City. He has authored some 240 peer-reviewed journal publications as well as more than 30 chapters of various textbooks, and he is nationally recognized for his outstanding contributions to urologic oncology. Dr. Cookson completed his Urology Residency at the University of Texas, San Antonio, and completed his Urologic Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in New York. From 1998 to 2013, he served as the Vice Chairman of Urologic Surgery and Director of the Urologic Oncology Fellowship Program at Vanderbilt University. Dr. Cookson has devoted much of his academic career to the management of patients with urologic cancers, with a strong emphasis on clinical guidelines, education, and evidenced-based medicine. He was a member of the AUA/ABU Examination Committee for 10 years, serving as Oncology Consultant and Pathology Editor. He also serves on the ABU Oral Examination Committee. He is a Co-Founder of the Oncology Knowledge Assessment Test (OKAT), an SUO-mandated examination. He also served as Chair for the OKAT for 5 years. In 2011, he received the President’s Distinguished Service Award from the SUO for educational contributions. He received the 2018 AUA Presidential Citation for Outstanding Service for his role in the development of the OKAT and as Chair of the Castration-Resistant Prostate Cancer Guidelines Committee at the AUA 2018 Annual Meeting. Dr. Cookson has previously served as a member of the AUA Guidelines on Localized Prostate Cancer Committee. Dr. Cookson is currently serving out the 2019-2020 term as the SUO President.

Talks by Michael S. Cookson, MD, MMHC

BCG Maintenance Should Be Less Intense

Posted by Michael S. Cookson, MD, MMHC | Jun 2019

Michael S. Cookson, MD, MMHC, suggests that the primary evidence does not provide convincing evidence in favor of 3 years of bacillus Calmette-Guérin (BCG) maintenance for non-muscle-invasive bladder cancer (NMIBC). He also notes that long-term BCG often leads to toxicities, contributing to low patient compliance.

Debate: Neoadjuvant Chemotherapy Prior to Cystectomy | Con Argument

Posted by Michael S. Cookson, MD, MMHC | May 2019

Michael S. Cookson, MD, argues that neoadjuvant chemotherapy (NAC) is not appropriate or necessary for all patients with muscle invasive bladder cancer (MIBC) prior to cystectomy. Instead, physicians should use a selective approach to NAC to avoid unnecessary harms, toxicities, and delays in local therapy.

Muscle Invasive Bladder Cancer: 2018 Guidelines

Posted by Michael S. Cookson, MD, MMHC | Apr 2019

Michael S. Cookson, MD, MMHC, reviews highlights from the recently released American Urological Association (AUA) Guidelines for muscle invasive bladder cancer (MIBC). He focuses on initial patient evaluation, the use of neoadjuvant chemotherapy, perioperative management, patient selection for bladder preservation, and surveillance following treatment.

Controversies in NMIBC: Guidelines and Beyond

Posted by Michael S. Cookson, MD, MMHC | Apr 2019

Michael S. Cookson, MD, MMHC, reviews practice-changing recommendations from recently updated guidelines for non-muscle invasive bladder cancer (NMIBC). He specifically emphasizes the importance of variant histology and risk-stratification in treatment decision-making for NMIBC.

MRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know

Posted by Michael S. Cookson, MD, MMHC | Mar 2019

Michael S. Cookson, MD, discusses prostate MRI as an upfront assessment for targeting lesions in biopsy naive patients and the conclusion from PROMIS and PRECISION regarding this application. He also reviews the potential applications of MRI in patients with prior negative biopsy and in those on active surveillance.